For Doctors Emergency Care Medikoe LogoDr Specialisation
Book AppointmentHealth HubMedicommunity
Home > Health Hub > Article > Burkitt Lymphoma: Diagnosis, Prognosis, Symptoms, and Treatments

Burkitt Lymphoma: Diagnosis, Prognosis, Symptoms, and Treatments

Medikoe Health Expert

Medikoe Health Expert

  Koramangala, bengaluru, karnataka, india, Bengaluru     Feb 9, 2017

   1 min     


Burkitt Lymphoma


Signs and symptoms

Burkitt and Burkitt-like lymphomas have a rapid and aggressive clinical course with frequent bone marrow and central nervous system (CNS) involvement. These are considered to be medical emergencies and require immediate diagnostic and therapeutic intervention.

Endemic (African) Burkitt lymphoma (eBL) most commonly involves the jaw and facial bone (orbit) (>50% of cases). Sporadic Burkitt lymphoma (sBL) most often presents as abdominal tumors with bone marrow involvement. Immunodeficiency-related Burkitt lymphoma cases usually as with nodal involvement with frequent bone marrow involvement.


The National Cancer Institute staging system is as follows:

A - Single solitary extra-abdominal site

AR - Intra-abdominal, more than 90% of tumor resected

B - Multiple extra-abdominal tumors

C - Intra-abdominal tumor

D - Intra-abdominal plus 1 or more extra-abdominal sites

The Ann Arbor system and St. Jude/Murphy staging (commonly used) consist of 4 stages.

Stage I is as follows:

Single tumor (extranodal)

Single anatomic area (nodal)

Stage II is as follows:

Single tumor (extranodal) with regional node involvement

Primary gastrointestinal tumor

Lymphoma involving nodal areas on the same side of the diaphragm

Stage IIR consists of completely resected intra-abdominal disease.

Stage III is as follows:

Lymphoma involving sites on opposite sides of the diaphragm

All primary intrathoracic tumors

All paraspinal or epidural tumors

Extensive intra-abdominal disease

Stage IV consists of any of the above, with CNS or bone marrow involvement (< 25%) at presentation.

The risk-adapted approach is used to treat most patients in the present-day clinical setting. Patients are divided into 2 broad groups, low- and high-risk patients. Low-risk patients have nonbulky disease (< 10 cm), early stage (I or II) disease, good performance status, and a normal lactate dehydrogenase (LDH) level. High-risk patients include all other patients.

Source :-

Tags:  Health care, cancer, ,

Note: We at Medikoe provide you with the best healthcare articles written and endorsed by experts of the healthcare industry to boost you knowledge. However, we strongly recommend that users consult a doctor or concerned service provider for expert diagnosis before acting on this information.

  2 Likes |    1 Comments |    0 Share |    610 Views

Vals Vals
Vals Vals |  September 14th, 2016

great article